Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Glazier

Clinical Nurse Specialist, Medical-Surgical Independence, MO Clinical Nurse Specialist

NPI 1790780898 CMS profile 10672640

19550 E 39Th St S, Suite 220, Independence, MO 64057

Open in the dashboard

General payments

$4,800

207 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Glazier of Independence, MO is reported in the CMS Open Payments database as having received $4,800 across 207 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Clinical Nurse Specialist, Medical-Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $601 30
2024 General $1,281 60
2023 General $864 41
2022 General $987 33
2021 General $1,067 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Glazier
  • Clinical Nurse Specialist, Medical-Surgical median
  • Middle half of Clinical Nurse Specialist, Medical-Surgical
  • National median

In program year 2025, general payments to Jennifer Glazier were reported at $601. Among 59 Clinical Nurse Specialist, Medical-Surgical profiles paid that year, the median was $165 and the middle half received between $54 and $254.

Show as a table
Year Jennifer Glazier Clinical Nurse Specialist, Medical-Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,067 $214 $58–$714 $132
2022 $987 $153 $29–$560 $149
2023 $864 $119 $27–$460 $160
2024 $1,281 $124 $52–$304 $164
2025 $601 $165 $54–$254 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $659 13 payments
  2. iRhythm Technologies, Inc. $576 24 payments
  3. Boston Scientific Corporation $533 16 payments
  4. Novartis Pharmaceuticals Corporation $524 32 payments
  5. Abbott Laboratories $456 19 payments
  6. Janssen Pharmaceuticals, Inc $373 12 payments
  7. Amgen Inc. $320 22 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $263 12 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $204 9 payments
  10. Pfizer Inc. $195 11 payments
  11. Other $697 37 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,800 207 payments
Products named General payments · program years 2021–2025
  1. ZIO XT Patch $576 24 payments
  2. LEQVIO $431 26 payments
  3. XARELTO $373 12 payments
  4. Micra $351 9 payments
  5. Zio monitor $321 13 payments
  6. Repatha $276 19 payments
  7. LifeVest $263 12 payments
  8. WATCHMAN FLX $222 12 payments
  9. General - Therapies $208 1 payment
  10. ENSITE PRECISION $204 9 payments
  11. Other $2,231 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

531

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$90,360

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

29%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 47 $39,314
Jardiance Empagliflozin Brand 29 $27,068
Xarelto Rivaroxaban Brand 24 $19,782
Atorvastatin Calcium Generic 77 $743
Metoprolol Succinate Generic 45 $579
Ranolazine Er Ranolazine Brand 16 $505
Carvedilol Generic 45 $389
Amiodarone Hcl Generic 21 $296
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 11 $283
Clopidogrel Clopidogrel Bisulfate Brand 27 $268

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$7,763

Medicare's payments for the services billed

Medicare patients

85

Average age 76

Services billed

110

39 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 65%
Arthritis 55%
Diabetes 53%
Chronic kidney disease 52%
Atrial fibrillation 46%
COPD 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $257
$257 — —
Repatha
  • Amgen Inc. $103
$103 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $54
$54 29 —
VYNDAQEL
  • PFIZER INC. $50
$50 — —
Wegovy
  • Novo Nordisk Inc $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

207 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Medical-Surgical in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record